Samsung BioLogics’ 2nd plant approved by US FDA

Published: 12/10/2017
Samsung BioLogics’ 2nd plant approved by US FDA
Source: WWW.KOREAHERALD.COM

Samsung BioLogics, a contract manufacturer of biologic drugs under South Korea’s Samsung Group, said Thursday that its second production plant in Songdo had been approved for commercial production by the US Food and Drug Administration. With the US FDA license, Samsung’s second plant equipped with 152,000 liters of production capacity is now able to commercially manufacture its first monoclonal an

Read more
Related news
Comment